Researchers have identified a key weakness in acute myeloid leukemia, offering a promising new strategy to delay the ...
Across the street from MD Anderson, at Texas Children's Hospital, Fivecoat's then-nearly 1-year-old granddaughter Whitney was ...
THRAP3, STMN1, and GNA13—are overrepresented in blood cancers like acute myeloid leukemia (AML) and could prove to be novel ...
Zacks.com on MSN1d
Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary GoalShares of Syros Pharmaceuticals SYRS plunged 86.9% on Wednesday after a late-stage study of its only pipeline candidate, ...
No one would begrudge Kathy Oliver if, even for a moment, she felt a little sorry for herself. But self-pity and pessimism just aren’t part of her character. “You’ve got to have a positive attitude, ...
Hematopoietic stem cell transplant (HSCT) after first complete remission appears more effective than non-HSCT consolidation in older patients with AML.
Syndax Pharmaceuticals (SNDX) stock dropped ~23% after the company posted Phase 2 trial data for its AML candidate, revumenib ...
On Tuesday, Syndax Pharmaceuticals Inc (NASDAQ:SNDX) revealed topline results from the relapsed or refractory (R/R) mutant ...
Blood cancer cases are rising alarmingly among young Indians, with leukemia incidences increasing and bone marrow transplants ...
Syros Pharmaceuticals’ blood cancer prospect tamibarotene has failed another ... Investors, already burnt by setbacks such as ...
A phase 2/3 study investigating uproleselan with standard 7+3 chemotherapy in newly diagnosed, older patients with acute ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback